Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
With the aging of society, the number of elderly patients with IgA nephropathy (IgAN) has been increasing. However, most clinical guidelines for IgAN do not provide age-specific treatment recommendations. In clinical practice, invasive therapies are often avoided in elderly patients due to the high risk of infection and multiple comorbidities, and previous reports have indicated that their renal prognosis is poor. In this study, we investigated proteinuria remission and renal prognosis in elderly patients with IgAN.
We conducted a retrospective cohort study of 74 patients aged ≥65 years among 1,132 patients diagnosed with IgAN by kidney biopsy at our hospital between 1977 and June 2024. Based on the initial treatment methods, we evaluated renal prognosis (50% eGFR decline or initiation of kidney replacement therapy) and proteinuria remission, and performed multivariate analysis to identify factors associated with sustained remission. Proteinuria remission was defined as proteinuria <0.3 g/day on at least three occasions over a 6-month period (Clin Exp Nephrol 2014). Furthermore, histological severity was assessed using the Japanese histological grade classification (J. Nephrol. 2013).
Among the 74 elderly patients, 64% were men, and the mean age was 70 years. Sixty-five percent were diagnosed after 2011. The mean proteinuria was 1.6 g/day, and the mean eGFR was 45.5 mL/min/1.73 m². Fifty-two percent had a Japanese histological grade classification ≥2 (25% or more of glomeruli showing crescents or global sclerosis), indicating advanced histologic findings. Glucocorticoids were used in 42% and renin–angiotensin system (RAS) inhibitors in 82% of patients. During a mean follow-up of 7.2 years, 28% progressed to 50% eGFR decline or end stage kidney disease requiring kidney replacement therapy, while 45% achieved proteinuria remission. There were no significant differences in renal prognosis or remission rates according to initial treatment. However, irrespective of treatment methods, renal prognosis was significantly better in patients who maintained proteinuria remission than in those who relapsed or never achieved remission (p = 0.004). In multivariate analysis, baseline proteinuria and histological severity were significantly associated with sustained remission, with odds ratios of 0.52 (95% CI, 0.23–0.96) and 0.30 (95% CI, 0.09–0.94), respectively.
Elderly patients with IgA nephropathy often present with heavy proteinuria, reduced renal function and advanced histological findings. Our findings suggest that maintaining remission of proteinuria is associated with a favorable renal prognosis.
